Shield Therapeutics (LON:STX) Stock Price Passes Below 50-Day Moving Average – Time to Sell?

Shares of Shield Therapeutics plc (LON:STX) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 3.06 ($0.04) and traded as low as GBX 3 ($0.04). Shield Therapeutics shares last traded at GBX 3.10 ($0.04), with a volume of 893,979 shares trading hands.

Shield Therapeutics Stock Performance

The company has a market cap of £29.61 million, a price-to-earnings ratio of -0.77 and a beta of 1.42. The company has a current ratio of 1.05, a quick ratio of 2.16 and a debt-to-equity ratio of 3,691.50. The stock’s fifty day simple moving average is GBX 3.07 and its 200 day simple moving average is GBX 3.39.

Insider Buying and Selling at Shield Therapeutics

In other news, insider Anders Lundstrom purchased 575,000 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of GBX 4 ($0.05) per share, for a total transaction of £23,000 ($29,750.36). 62.16% of the stock is owned by insiders.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.